JeffreyVictorMatousMD
Hematology • Denver, COHematologic Oncology
Member Colorado Blood Cancer Institute Sarah Cannon Research Institute Clinical Professor of Medicine, University Colorado
Dr. Matous is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1721 E 19th Ave
#300
Denver, CO 80218- Is this information wrong?
Summary
- Dr. Jeffrey Matous is a hematologist in Denver, CO and is affiliated with Presbyterian/St. Luke's Medical Center. He received his medical degree from University of Washington School of Medicine and has been in practice 32 years. He specializes in hematologic oncology and his practice focuses on amyloidosis, multiple myeloma, waldenstrom's macroglobulinemia, and stem cell transplantation.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1990 - 1994
University of ColoradoResidency, Internal Medicine, 1985 - 1989- University of Washington School of MedicineClass of 1985
Certifications & Licensure
MT State Medical License 2004 - 2025
CO State Medical License 1988 - 2025
NE State Medical License 2003 - 2022- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor Start of enrollment: 2004 Mar 01
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation Start of enrollment: 2005 Nov 01
- Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant Start of enrollment: 2007 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn E Wahlin, Ramón García-Sanz, Helen McCart...> ;Blood Advances. 2024 Apr 9
- 5 citationsZanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn E Wahlin, Ramon Garcia-Sanz, Helen Mc...> ;Journal of Clinical Oncology. 2023 Nov 20
- 1 citationsBTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.Marzia Varettoni, Jeffrey V Matous> ;Hematology/oncology Clinics of North America. 2023 Aug 1
- Join now to see all
Journal Articles
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s MacroglobulinemiaJeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine
Abstracts/Posters
- A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...Jeffrey V. Matous, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Presbyterian/St. Luke's Medical CenterDenver, Colorado
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
